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Abstract
Despite the initial response to the reversible, ATP-competitive quinazoline inhibitors that target ErbB-family, such a subset
of cancer patients almost invariably develop resistance. Recent studies have provided compelling evidence that irreversible
ErbB inhibitors have the potential to override this resistance. Here, we found that AST1306, a novel anilino-quinazoline
compound, inhibited the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as
EGFR resistant mutant in both cell-free and cell-based systems. Importantly, AST1306 functions as an irreversible inhibitor,
most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively.
Further studies showed that AST1306 inactivated pathways downstream of these receptors and thereby inhibited the
proliferation of a panel of cancer cell lines. Although the activities of EGFR and ErbB2 were similarly sensitive to AST1306,
ErbB2-overexpressing cell lines consistently exhibited more sensitivity to AST1306 antiproliferative effects. Consistent with
this, knockdown of ErbB2, but not EGFR, decreased the sensitivity of SK-OV-3 cells to AST1306. In vivo, AST1306 potently
suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N
neu transgenic breast cancer
mouse models, but weakly inhibited the growth of EGFR-overexpressing tumor xenografts. Tumor growth inhibition
induced by a single dose of AST1306 in the SK-OV-3 xenograft model was accompanied by a rapid (within 2 h) and
sustained ($24 h) inhibition of both EGFR and ErbB2, consistent with an irreversible inhibition mechanism. Taken together,
these results establish AST1306 as a selective, irreversible ErbB2 and EGFR inhibitor whose growth-inhibitory effects are
more potent in ErbB2-overexpressing cells.
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Introduction
The ErbB tyrosine kinase superfamily, comprising the epider-
mal growth factor receptor (EGFR; also known as ErbB1/HER1),
ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4), plays
important roles in cancer development and progression [1]. Upon
binding their cognate ligands (e.g., EGF, transforming growth
factor-a), these receptors form active homodimers and heterodi-
mers. No ligand has been identified for ErbB2; instead, this protein
functions as a coreceptor by binding to other receptors in the
family [2]. Activation of ErbB family receptors results in
subsequent recruitment and phosphorylation of several intracellu-
lar substrates, including components of the Ras-Raf-MAPK
(mitogen-activated protein kinase) and the PI3K (phosphoinositide
3-kinase)-AKT pathways, leading to mitogenic signaling and other
cellular activities [3,4]. Dysregulation of ErbB receptor activity
through overexpression or mutation is associated with a number of
different cancers; thus, members of the ErbB family have become
important therapeutic targets in several types of cancer.
Numerous reversible ErbB tyrosine kinase inhibitors (TKIs) are
currently in development for cancer therapy. Several such
inhibitors have been approved for use in cancer patients, including
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lapatinib (GW572016, Tykerb) [5,6,7]. However, treatment with
these reversible TKIs produces objective responses in a rather
small subset of patients, possibly corresponding to individuals with
activating mutations in the EGFR tyrosine kinase domain, such as
the L858R mutation [8,9]. Despite positive initial response, these
patients almost invariably develop acquired secondary resistance,
such as substitution of threonine 790 with methionine (T790M), to
these reversible inhibitors and relapse after several months
[10,11,12], which accounts for about half of all cases of resistance
to gefitinib and erlotinib [13,14]. Therefore, resistance to
reversible ErbB inhibitors has emerged as a significant clinical
problem.
Recent studies have revealed that acquired EGFR mutations
remain sensitive to irreversible ErbB inhibitors. Oral administra-
tion of these irreversible inhibitors produces significant anti-tumor
activity in a variety of human tumor xenograft models that express
or overexpress ErbB family members, especially those that contain
the EGFR double mutation, L858R/T790M [15,16]. Thus,
irreversible EGFR inhibitors potentially provide a second-line
treatment for managing resistance to reversible EGFR inhibitors.
Several of these inhibitors, namely HKI-272 [17], EKB-569 [18],
BIBW2992 [19,20] and PF00299804 [21], are currently under-
going clinical testing; however, none of them have yet received
approval by FDA.
We rationally designed and synthesized a series of quinazoline
derivatives based on the chemical structure of lapatinib,
combining the key chemical group of irreversible EGFR
inhibitors. One such derivative, AST1306, stood out in these
screens and was selected for further evaluation. In this report, we
evaluated the in vitro and in vivo antitumor activity of AST1306 and
identified it as a novel irreversible ErbB family inhibitor. AST1306
potently inhibits wild-type EGFR and ErbB2, as well as EGFR
mutants, in both cell-free and intact cell assays. Moreover, ErbB2-
overexpressing tumors are more sensitive to the growth-inhibitory
effects of AST1306 than are EGFR-overexpressing tumors, both in
vitro and in vivo. Our data establish AST1306, which is currently in
phase I clinical trial in China, as a novel irreversible ErbB
inhibitor that deserves further development.
Materials and Methods
Cell culture
SK-OV-3, BT474, MDA-MB-468, Calu-3, A-549, NCI-H23,
NCI-H1975 and NIH3T3 cells were obtained from the American
Type Culture Collection (Rockville, MD). HO-8910 cells were
obtained from the cell bank of the Chinese Academy of Sciences.
MCF-7 cells were obtained from the Japanese Foundation of
Cancer Research. NIH3T3 cells that overexpressed EGFR
T790M/L858R mutant (NIH3T3-EGFR T790M/L858R) were
constructed and maintained in our laboratory. All cell lines were
maintained in strict accordance with the supplier’s instructions and
established procedures.
Cell proliferation, tyrosine kinase, and Western blot assay
The cell proliferation assay was evaluated using SRB (Sulforho-
damine B) assay treated for 72 h with indicated concentrations of
AST1306. The tyrosine kinase activities were determined using
enzyme-linked immunosorbant assay (ELISA). The serine/threo-
nine kinase activities were detected by Caliper Mobility Shift Assay
on EZ Reader (Caliper Life Sciences, MA) according to the
instruction. For analysis of receptor tyrosine kinase phosphoryla-
tion and downstream signal transduction pathways in human
cancer cells, starved cells were treated with AST1306 for 4 h and
stimulated with EGF (50 ng/ml) for 15 min, and then collected
and processed for Western blot analysis (ref. [22,23,24]; see Text
S1 for a complete description).
Molecular docking simulation
The crystal structure of EGFR kinase domain in complex with
lapatinib (PDB entry 1XKK) [25] was used as EGFR target for
molecular docking simulation. 3D models of the ErbB2 kinase
domain was created according to highly homologous protein
EGFR by employing MODELLER program [26]. Ten models of
each enzyme were generated and all these 3D structures were
optimized with conjugate gradient minimization scheme followed
by a restrained simulated annealing molecular dynamics simula-
tion. The one with the lowest value of the objective function was
selected as a representative target model for further study.
Structure-based analysis was performed using the docking
program AUTODOCK4.0 [27]. The Lamarckian genetic algo-
rithm (LGA) was applied with the step size set to 0.2 A ˚ for
translation and 5u for orientation and torsion. The number of
generation, energy evaluation, and docking runs were set to
500,000, 2,500,000 and 20, respectively. Ligand poses with the
lowest binding energy were then used to analyze the interaction
mode between the ligand and its different targets.
Irreversibility assessments for AST1306
Rapid dilution experiments as described previously [25] were
used to demonstrate irreversible binding of AST1306 to EGFR
and ErbB2. Nine microliters of 100-fold normal amount of
enzyme (800 nM for EGFR, 1800 nM for ErbB2) was mixed with
1 mL of AST1306 at a final concentration of 100-fold IC50 for
each enzyme or with vehicle control (DMSO). Lapatinib was used
as a positive control compound. After incubation at room
temperature for 30 minutes, 1 mL of the mix solution of was
diluted into 99 mL of a solution containing substrate peptide
(sequence: 5-FAM-EEPLYWSFPAKKK-CONH2, 1.5 mM) and
ATP (2.3 mM for EGFR, 15 mM for ErbB2). The microplate was
placed in the EZ Reader (Caliper Life Sciences, MA) and wells
were repeatedly sampled for 180 minutes.
Small interfering RNA transfection
Small interfering RNA (siRNA) against EGFR or ErbB2, as well
as control siRNA, were designed and synthesized by Shanghai
GenePharma Co. Ltd. One pair of ErbB2 siRNA (sequence: 59
CGUUUGAGUCCAUGCCCAATT 39), and two pairs of EGFR
siRNA (#1 sequence: 59 GGUAGUAAAUAUGAAACUATT 39;
#2 sequence: 59 GUCCUUGGGAAUUUGGAAATT 39) were
applied in this study. Different kind of siRNA (final concentration:
50 nmol/L) was transfected to SK-OV-3 cells with oligofectamine
reagent (Invitrogen) according to the manufacturer’s instruction.
AST1306 treatment was done 48 h after transfection. Growth-
inhibitory effects of AST1306 on the cells were determined by
SRB assay.
Suppression of tumor growth in human tumor xenograft
models and tumor extract analyses
The mice were housed and maintained under specific-
pathogen free (SPF) conditions. All animal procedures were
performed according to the protocol approved by the Institu-
tional Animal Care and Use Committee at Shanghai Institute of
Materia Medica, Chinese Academy of Sciences (SIMM-AE-DJ-
2010-01). Under sterile conditions, well-developed tumors were
cut into 1-mm
3 fragments and transplanted s.c. into the right
flank of nude mice using a trocar. When the tumor reached a
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3, the mice were randomly
assigned into control and treatment groups. Control groups were
given vehicle alone, and treatment groups received AST1306
(100, 50 and 25 mg/kg) or lapatinib (50 mg/kg) (p.o, twice daily).
The sizes of the tumors were measured twice per week using
microcalipers. The tumor volume (V) was calculated as follows:
V=(length6width
2)/2. The body weights of the mice were
observed simultaneously.
To assess the pharmacodynamic effect in tumors, mice bearing
established (,200 mm
3) SK-OV-3 xenograft tumors were treated
with a single dose of AST1306 at 100 mg/kg. Tumors were
harvested at indicated times (n=3 per time point) after treatment,
immediately frozen in liquid nitrogen, and then homogenized in
500 mL protein extraction solutions (SBS Genetech, Shanghai,
China). Tumor extracts were subjected to SDS-PAGE followed by
immunoblotting.
Antitumor activity against spontaneity breast cancer in
FVB-2/N
neu transgenic mouse
Thirty eight- to forty four-week-old female FVB/N
neu mice
were obtained from Shanghai Laboratory Animal Center. The
animals were housed under specific pathogen-free conditions. The
solution of AST1306 was suspended in 0.5% hydroxypropyl
methylcellulose (HPMC), grinding with agate mortar. Mice were
administered AST1306 at dosage of 100, 50 and 25 mg/kg twice
daily and treated with lapatinib (50 mg/kg) as comparison.
Tumors were measured twice a week in two dimensions, using a
caliper, and the tumor volume was calculated according to the
formula L6W6W/2.
Statistical analysis
Data are expressed as the mean 6 SD, and differences were
considered significant at P,0.05 determined by t test.
Results
AST1306 selectively inhibits the tyrosine kinase activities
of EGFR and ErbB2 in vitro
The compound AST1306 was synthesized as described in Text
S1, and its chemical structure is shown in Fig. 1. We first examined
the inhibitory activities of AST1306 by performing in vitro assays
against EGFR, ErbB2 and 23 other kinases. AST1306 was a
potent inhibitor of EGFR and ErbB2 in a cell-free assay,
exhibiting IC50 values of 0.5 and 3 nmol/L, respectively
(Table 1). Notably, AST1306 was more than 3000-fold selective
for ErbB family kinases over other kinase families tested in the
present study (Table 1). AST1306 is thus a potent selective
inhibitor of EGFR and ErbB2.
AST1306 irreversibly binds EGFR and ErbB2
AST1306 was designed to be an irreversible ErbB family
inhibitor. To verify this, we determined the reversibility of EGFR
and ErbB2 binding using a dilution method. In this approach, an
amount of receptor 100 times that normally used in a reaction is
preincubated for 30 min with a concentration of AST1306 100-
fold greater than the IC50 value or with the vehicle control. After
incubating, the enzyme/inhibitor mixture is diluted 100-fold (i.e.,
to normal reaction conditions), reaction buffer plus ATP and
substrate are added, and receptor kinase activity is measured
continuously. In general, a reversible inhibitor dissociates quickly,
allowing immediate recovery of enzymatic activity, whereas a
slowly reversible inhibitor allows a gradual increase in activity. In
contrast, an irreversible inhibitor prevents recovery of enzymatic
activity. As shown in Fig. 2A, virtually no EGFR or ErbB2
activity was recovered after incubating with AST1306, convinc-
ingly demonstrating that AST1306 is an irreversible inhibitor of
EGFR and ErbB2. Reactions containing lapatinib, a slowly
reversible inhibitor of EGFR and ErbB2, used as a control,
revealed a slow recovery of the enzymatic activity, consistent with
previous report [25].
Figure 1. Chemical structure of AST1306.
doi:10.1371/journal.pone.0021487.g001
Table 1. In vitro inhibitory activity of AST1306 on different
kinds of kinase.
Kinase IC50
a, nmol/L
EGFR 0.560.2
ErbB2 3.061.5
ErbB4 0.860.3
Flt-1 .10000
KDR .10000
PDGFRa .10000
PDGFRb .10000
c-Src .10000
c-Met .10000
c-Kit .10000
IGF1R .10000
FGFR1 .10000
RON .10000
Abl .10000
EphA2 .10000
EphB2 .10000
Tie2 .10000
SYK .10000
PKCb2 .10000
p70S6K .10000
JAK2 .10000
Pim2 .10000
AKT1 .10000
AUR A .10000
CDK2 .10000
GSK3b .10000
EGFR T790M/L858R 1262
aIC50, the concentration of AST1306 inducing 50% inhibition of kinase activity.
IC50s were calculated by Logit method and expressed as means 6 SD.
doi:10.1371/journal.pone.0021487.t001
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acids of EGFR and ErbB2
The observation that AST1306 potently, selectively and
irreversibly inhibited EGFR and ErbB2 prompted us to further
investigate the mode of AST1306 binding to its targets. Using a
molecular docking method and a previously described molecular
model of EGFR with lapatinib, we docked AST1306 into the
ATP-binding pocket of the EGFR kinase domain (Fig. 2B, left
panel). The results of this analysis showed that AST1306 was
surrounded by hydrophobic residues in the ATP-binding pocket of
EGFR. Importantly, the b-carbon atom of the Michael acceptor is
predicted to be located at a distance of 4.4 A ˚ from the sulfur atom
of Cys-797, which is known to be a critical residue for irreversible
inhibitor binding and should be easily accessible for the covalent
interaction. A similar mode was also predicted for AST1306
binding to our homology model of ErbB2. As shown in Fig. 2B
(right panel), in addition to the hydrophobic interactions with
ErbB2, AST1306 was predicted to form covalent interaction with
Cys-805, which is also known to be a critical residue for
irreversible inhibitor binding to ErbB2. These results demonstrate
that AST1306 might covalently bind to specific amino acid
residues of EGFR and ErbB2, consistent with previous reports of
irreversible inhibitors, such as EKB-569 [28].
AST1306 inhibits the tyrosine kinase activity of the EGFR
mutant T790M/L858R in cell-free and intact cell assays
The EGFR T790M/L858R mutant confers resistance in
patients treated with reversible ErbB inhibitors, but is known to
retain sensitivity to irreversible ErbB inhibitors. Accordingly, we
tested whether AST1306 possesses inhibitory activity toward
EGFR T790M/L858R in a cell-free system. AST1306 potently
inhibited the EGFR T790M/L858R double mutant, exhibiting an
IC50 value of 1262 nmol/L (Table 1), which was approximately
500-fold more potent than lapatinib (IC50.5000 nmol/L; data
not shown). We next determined the inhibitory activity of
AST1306 toward this EGFR double mutant at the cellular level.
As shown in Fig. 3A, AST1306 induced a significant, concentra-
tion-dependent inhibition of the growth of HIH3T3-EGFR
T790M/L858R cells. In contrast, it was much less potent toward
parental NIH3T3 cells. In addition, AST1306 effectively inhibited
EGFR phosphorylation in HIH3T3-EGFR T790M/L858R cells,
whereas lapatinib showed much weaker inhibitory effect on it.
(Fig. 3B). Moreover, AST1306 inhibited the growth of NCI-
H1975 cells that harbor the EGFR T790M/L858R mutation in a
concentration-dependent manner (Fig. 3C), and blocked phos-
phorylation of EGFR and downstream pathways as well (Fig. 3D).
These results suggest that AST1306, like other irreversible
inhibitors, may overcome the acquired resistance to reversible
inhibitors.
AST1306 inhibits the phosphorylation of EGFR and ErbB2,
and downstream signaling in human cancer cells
We next evaluated the targets inhibition of AST1306 in human
cancer cells that overexpress EGFR and/or ErbB2. AST1306
dose-dependently and markedly inhibited EGF-induced EGFR
phosphorylation in A549 cells, which are known to express high
levels of EGFR. As shown in Fig. 4A, the bands of phospho-EGFR
almost disappeared after the treatment of AST1306 at 0.01 mM
concentration. Activity of the downstream pathways of EGFR was
also decreased in dose-dependent manner after treatment with
AT1306, as evidenced by decreased phosphorylation of Erk1/2
and AKT (Fig. 4A). Of note, the bands of phospho-Erk1/2 and
Figure 2. AST1306 irreversibly binds EGFR and ErbB2. A, Recombinant EGFR (left panel) or ErbB2 (right panel) was preincubated for 30 min
with or without AST1306 or lapatinib at a concentration 100-fold in excess of the respective IC50 value in the absence of substrate, and then diluted
and assayed for enzymatic activity. B, The binding mode of AST1306 with EGFR (left panel) or ErbB2 (right panel) predicted by the molecular docking
simulations. Key distances and related amino acid residues are shown in the figure and discussed in detail in the text.
doi:10.1371/journal.pone.0021487.g002
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tion of AST1306 than that of phospho-EGFR inhibition, which
might due to the crosstalk between different signaling pathways or
other potential mechanism of this compound.
Moreover, we also detected the targets inhibition and
downstream signaling inhibition of AST1306 in other cancer cell
lines. Similar results were also obtained in ErbB2-overexpressing
Calu-3 cells (Fig. 4B) and SK-OV-3 cells that overexpress both
EGFR and ErbB2 (Fig. 4C). Notably, AST1306 was a .10-fold
more potent inhibitor of targets and the downstream signaling
than the reference compound lapatinib in the human cancer cells
tested.
AST1306 inhibits the proliferation of human cancer cells,
with ErbB2- overexpressing cells exhibiting more
sensitivity
The antiproliferative effects of AST1306 were then evaluated in
a panel of human cancer cell lines with varying levels of EGFR
and ErbB2 expression. As shown in Fig. 5A, AST1306 effectively
suppressed the proliferation of human cancer cell lines; however,
the IC50 values varied widely among them. The Calu-3 lung
adenocarcinoma and BT474 breast cancer cell line, containing
high levels of ErbB2, were more sensitive to AST1306, with IC50
values of 0.23 and 0.97 mmol/L, respectively. In contrast, cell lines
with high levels of EGFR but lower levels of ErbB2 (MDA-MB-
468, A549 and NCI-H23) or high levels of both ErbB2 and EGFR
(SK-OV-3) were less sensitive to AST1306, with an IC50 values
ranging from 6.2 to 7.5 mmol/L. The MCF-7 cell line, which
expresses low levels of both EGFR and ErbB2, was the least
sensitive to AST1306, with IC50 value of 16.0 mmol/L. Moreover,
we also detected the activity of AST1306 on anchorage-
independent growth of SK-OV-3 cells and A549 cells, respective-
ly. As shown in Figure S1, AST1306 can dramatically inhibit the
growth of both tumor cells on soft agar, and SK-OV-3 cells
exhibited much more sensitivity than that of A549 cells. These
results indicate that AST1306 inhibits the proliferation of human
cancer cell lines in vitro, and suggest that ErbB2 expression is
associated with a consistently higher sensitivity to AST1306 across
the various cell lines tested.
Silencing of ErbB2, but not EGFR, decreases the
sensitivity of SK-OV-3 cells to AST1306
The above results revealed that although AST1306 potently
inhibited EGFR and ErbB2 enzymatic activities in a cell-free assay
and significantly dephosphorylated EGFR and ErbB2 at the
cellular level, proliferation was more sensitive to inhibition by
Figure 3. Effects of AST1306 on cells harboring the EGFR T790M/L858R double mutant. A, Inhibition by AST1306 of the proliferation of
NIH3T3 parental cells and NIH3T3 cells engineered to express EGFR T790M/L858R double mutant. Cells were treated with the indicated
concentrations of AST1306 for 72 h. Cell viability was determined using sulforhodamine B assay. IC50 values were determined based on the results of
three independent experiments. B, AST1306 inhibits the phosphorylation of EGFR in NIH3T3-EGFR T790M/L858R cells. Cells were cultured in the
presence of different concentrations of AST1306 for 6 h and harvested. Whole-cell lysates were assayed for total EGFR and phosphorylation of EGFR
by immunoblotting. A representative anti-GAPDH immunoblot is shown as a loading control. C, Growth inhibition of NCI-H1975 cells by AST1306. Cell
viability was determined using sulforhodamine B assay. D, AST1306 inhibits EGF-induced phosphorylation of EGFR and that of downstream signaling
molecules in NCI-H1975 cells.
doi:10.1371/journal.pone.0021487.g003
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overexpressing cell lines. To address this discrepancy, we
examined AST1306 sensitivity upon knockdown of EGFR and
ErbB2. First of all, we tested the activity of siRNA transfection on
proliferation of SK-OV-3 cells, and found that it had no obvious
effects on the cell proliferation (Figure S2). And then, the siRNA
was transfected into SK-OV-3 cells and treated with AST1306 or
vehicle. As shown in Figure 5B, SK-OV-3 cells transfected with
ErbB2 siRNA were significantly more resistant to treatment with
AST1306 at concentrations of 6.25 mmol/L (p,0.05) or
12.5 mmol/L (p,0.01). However, knocking down EGFR expres-
sion using two independent pairs of EGFR siRNAs did not
significantly affect the antiproliferative activity of AST1306
(Fig. 5B). These results suggest that ErbB2 plays a more important
role in the sensitivity to the antiproliferative effects of AST1306
than does the EGFR, at least in SK-OV-3 cells.
Figure 4. AST1306 inhibits the activation of tyrosine kinases and downstream signaling pathways in A549 cells (A), Calu-3 cells (B)
and SK-OV-3 cells (C). Cells were starved in serum-free medium for 24 h and then cultured in the presence of varying doses of AST1306 for 4 h at
37uC in medium without FBS. EGF (50 ng/ml) was then added. After a 15-min incubation at 37uC, whole -cell lysates were harvested and assayed by
Western blotting.
doi:10.1371/journal.pone.0021487.g004
Figure 5. Antiproliferative activities of AST1306 in vitro. A, Antiproliferative activities of AST1306 in human cancer cell lines in vitro were
determined using a sulforhodamine B assay. B, Knockdown of ErbB2, but not EGFR, leads to AST1306 resistance in SK-OV-3 cells (*P,0.05; **P,0.01).
Each experiment was repeated three times independently.
doi:10.1371/journal.pone.0021487.g005
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overexpressing xenograft models
Given its encouraging in vitro activity, we examined the
antitumor efficacy of AST1306 in vivo. Specifically, we measured
the antitumor activity of AST1306 in two different human ovarian
cancer xenograft nude mice models (SK-OV-3 and HO-8910),
and two different human lung cancer xenograft nude mice models
(Calu-3 and A549). SK-OV-3 and Calu-3 are known to be ErbB2-
overexpressing tumors, whereas HO-8910 and A549 tumors
express low levels of ErbB2. As shown in Fig. 6A, twice daily oral
administration of AST1306 caused a dramatic suppression of
tumor growth in SK-OV-3 and Calu-3 xenograft models. In SK-
OV-3 models, tumors almost completely disappeared after
treatment with AST1306 for 7 d. In contrast, AST1306 only
slightly suppressed tumor growth in HO-8910 and A549 xenograft
models (Fig. 6A). These results demonstrate that the antitumor
efficacy of AST1306 is greater in ErbB2-overexpressing tumor
models than in models expressing low levels of ErbB2, consistent
Figure 6. In vivo activity of AST1306 in xenograft models and FVB-2/N
neu transgenic mouse model. A, Inhibitory effects of AST1306 on
tumor growth in human tumor xenograft models. Body weights of the nude mice were measured concurrently (B). C, Inhibition of target (EGFR and
ErbB2) activation by AST1306 in tumors. Nude mice bearing established (,200 mm
3) SK-OV-3 tumors were treated with a single dose of AST1306
(100 mg/kg). Tumors were harvested at the indicated times after treatment and immediately frozen in liquid nitrogen. Western blot analysis was
performed to determine the levels of phosphorylated EGFR and ErbB2. D, Activity of AST1306 in FVB-2/N
neu transgenic mouse model.
doi:10.1371/journal.pone.0021487.g006
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mediated inhibition assays. Body weights of nude mice measured
concurrently showed no obvious differences during the treatment
(Fig. 6B), demonstrating that AST1306 was well tolerate.
Lapatinib also exhibited antitumor activity in these ErbB2-
overexpressing tumor models, but AST1306 was more efficacious
than lapatinib in the SK-OV-3 xenograft tumor model when given
at the same dose and schedule.
We also examined inhibition of target activity by measuring
EGFR and ErbB2 phosphorylation levels in tumor extracts at
indicated times after a single administration of AST1306. As
shown in Fig. 6C, inhibition of EGFR and ErbB2 activation by
AST1306 was clearly evident in tumors within 2 h after treatment.
Notably, these inhibitory effects lasted at least 24 h.
AST1306 inhibits the tumor growth of FVB-2/N
neu
transgenic mouse model
To further confirm that AST1306 possesses inhibitory activities
in ErbB2-overexpressing models, we evaluated the antitumor
activity of AST1306 in FVB-2/N
neu transgenic mouse model,
which expresses the ErbB2/Neu proto-oncogene and closely
recapitulates the ontogeny and progression of human breast
cancer [29]. As shown in Fig. 6D (left panel), oral administration of
AST1306 twice daily for 3 wk caused a dramatic suppression of
tumor growth in the FVB-2/N
neu models; after treatment for 11 d,
tumors almost completely disappeared. The body weights of the
mice decreased by less than 20% during treatment (Fig. 6D, right
panel).
Discussion
Resistance to reversible ErbB tyrosine kinase inhibitors has
recently emerged as a crucial problem for targeted cancer therapy.
The development of additional irreversible inhibitors, which have
proven to be effective in overcoming treatment-resistant EGFR
mutant, is warranted. In the present study, we have provided
convincing evidence that AST1306 is a novel irreversible inhibitor
of EGFR and ErbB2, which is superior to lapatinib. Using
molecular docking models, we demonstrated that AST1306 can
dock into the ATP-binding pocket of EGFR and ErbB2. Notably,
the interactions between the Michael acceptor functional group of
AST1306 and the corresponding critical cysteines of EGFR and
ErbB2 are likely to result in covalent binding of AST1306 to the
enzymes.
The most exciting potential for irreversible inhibitors is their
ability to inhibit mutant forms of ErbB family members. EGFR
L858R, one of the most common activating mutations, allows
gefitinib to move deeper into the binding pocket, enhancing the
interaction between gefitinib and the receptor [30]. T790M, a
secondary resistance mutation in the EGFR kinase domain, leads
to the steric hindrance in the binding of reversible EGFR
inhibitors [31], and/or increases the affinity for ATP [32], and
thus results in resistance to reversible inhibitors. The EGFR
T790M/L858R double mutation is a common mutation that
appears in clinical lung cancer patients treated with reversible
inhibitors [10]. Our studies showed that AST1306 potently
inhibited the EGFR T790M/L858R double mutant in both cell-
free and cell-based assay, including NIH3T3 cells engineered to
express the T790M/L858R mutant and NCI-H1975 cells, which
endogenously express this mutant. These findings provide
compelling evidence that AST1306, as an irreversible ErbB
inhibitor, clearly possessed inhibitory activity toward EGFR
resistant mutations, demonstrating that AST1306 may have
potential utility in patients whose tumors are unresponsive to
reversible inhibitors. Future investigation will be required to assess
the in vivo efficacy of AST1306 in tumors that harbor secondary
mutations in their ErbB receptor.
Mounting evidence has verified that ErbB2 is an important
component of the ErbB signaling network in human cancer cells.
Lacking a known endogenous ligand, ErbB2 appears to exist
predominantly in an active conformation ready to heterodimerize
with other ErbB family members; thus, ErbB2 containing
heterodimers are more efficiently activated, especially in settings
where ligand is limiting [33]. Moreover, ErbB2 expression may
increase EGFR recycling to the membrane and prevent its
degradation, a process that may also make a significant
contribution to ErbB2 function. These properties make ErbB2
more important than other members of the ErbB family in certain
respects and thus attract increasing attention in recent years. In the
present study, we clearly demonstrated that high expression of
ErbB2 in tumor cells were associated with enhanced sensitivity to
the antiproliferative and antitumor effects of AST1306. Results
from siRNA-mediated knockdown of EGFR and ErbB2 provided
further support for this phenomenon. This property of AST1306 is
consistent with that of lapatinib that its activity is not dependent on
EGFR expression level in ErbB2-overexpressing breast cancer
cells [34]. These notions provide strong evidence that, despite
comparable biological inhibitory activity of AST1306 toward
EGFR and ErbB2 tyrosine kinases in cell-free assays, the growth-
inhibitory effect of AST1306 in human cancer cells and in
xenograft tumor models tracks more closely with its anti-ErbB2
effects. Given other known irreversible ErbB inhibitors, HKI-272,
BIBW2992, CI1033, and PF-00299804 are active in both EGFR-
and ErbB2-dependent tumor xenograft models [15,19,20,35,
36,37], whereas EKB569 shows poorer efficacy in ErbB2-
dependent tumor modes than in EGFR-dependent models [35],
our results that AST1306 is more efficacious in ErbB2- than
EGFR-dependent models suggest that AST1306 is somewhat
different from the known irreversible ErbB family inhibitors.
Another attractive property exhibited by irreversible inhibitors
is their prolonged pharmacokinetic effects. Once an irreversible
inhibitor deactivates the target enzyme by covalent bond
formation, its biological effects should persist even after the drug
leaves the circulation. Consistent with this feature, EGFR and
ErbB2 phosphorylation was inhibited for more than 24 h after
AST1306 treatment in the SK-OV-3 human ovarian carcinoma
xenograft model. Because the half-life of AST1306 after a single
oral dose (90 mg/kg) is less than 3.6 h and 2.3 h in rats or in dogs,
respectively (unpublished data), the sustained inhibition of
phosphorylation seen in the xenograft studies of AST1306 allows
the once- or twice-daily oral dosing. Taken together, these
attributes of AST1306 would be expected to reduce the
nonspecific interactions that might occur at high or prolonged
plasm levels and thus reduce toxicity.
Given the critical importance of ErbB receptors in maintaining
the neoplastic properties of a variety of cancers and the
incompletely met medical need for effective cancer treatment,
the results of the present study, combined with the better
pharmacokinetic profiles and well-tolerated toxic settings (unpub-
lished data), indicate that AST1306 deserves further study,
especially in the context of human tumors that overexpress ErbB2
and/or harbor secondary mutations in their ErbB receptors.
Supporting Information
Figure S1 AST1306 suppressed anchorage-independent
cell growth of SK-OV-3 cells (A, C) and A549 cells (B, D).
Cells (8000/mL) were expose to AST1306 in 1 mL of
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The culture was maintained at 37uC in a 5% CO2 atmosphere for
two weeks. The average colony number was calculated and
colonies were photographed. Columns, mean of triplicate samples;
bars, SE. Significant differences were evaluated using the Student’s
test (*P,0.05; ** P,0.01).
(TIF)
Figure S2 Different kinds of siRNA (50 nmol/L) were
transfected to SK-OV-3 cells with oligofectamine reagent
(Invitrogen) according to the manufacturer’s instruc-
tion. Forty eight hours after transfection, growth effects of these
siRNAs on the cells were determined by SRB assay.
(TIF)
Text S1 Detailed description of Materials and Methods.
(DOC)
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